Zogenix Inc. (NASDAQ:ZGNX) saw a large growth in short interest in the month of January. As of March 14th, there was short interest totalling 13,436,836 shares, a growth of 23.2% from the February 28th total of 10,903,479 shares, Stock Ratings Network.com reports. Based on an average trading volume of 6,419,426 shares, the days-to-cover ratio is currently 2.1 days. Currently, 12.7% of the company’s shares are sold short. Zogenix, Inc. (NASDAQ:ZGNX) weekly performance is -5.49%. On last trading day company shares ended up $2.58. Zogenix, Inc. (NASDAQ:ZGNX) distance from 50-day simple moving average (SMA50) is -35.68%. Analysts mean target price for the company is $5.73.
Green Gro Technologies, Inc. (OTCMKTS:GRNH), released that it has concluded the acquisition of Roseville, California based Vertical Hydrogarden. Green Gro Technologies, Inc. (OTCMKTS:GRNH) shares fell -4.35% in last trading session and ended the day on $0.440.
Sun Coke Energy, Inc. (NYSE:SXC) reported first quarter 2014 domestic coke production is expected to be 944 thousand tons, down an estimated 108 thousand tons versus the same prior year period. This year-over-year decline reflects approximately 64 thousand tons of lower production at our Indiana Harbor facility due to the combined impact of severe winter weather and the significant refurbishment effort underway at this plant. The extreme winter weather, which impacted charge weights and yield, drove nearly 40 thousand tons of lower production at our Haverhill and Granite City operations collectively. Sun Coke Energy Inc (NYSE:SXC) shares moved down -0.09% in last trading session and was closed at $23.30, while trading in range of $23.18 – 23.90. Sun Coke Energy Inc (NYSE:SXC) year to date (YTD) performance is 2.15%.
Ventrus Biosciences, Inc. (NASDAQ:VTUS) announced that, in response to a request from the company, the U.S. Food and Drug Administration (FDA) has scheduled a Type B pre-NDA meeting on Thursday, June 19, 2014 at which the company will seek guidance on its planned new drug application (NDA) for DOLIZEM (diltiazem hydrochloride cream) in anal fissures. Ventrus would expect to file an NDA in the second half of 2014 with an anticipated PDUFA date in the second half of 2015 if there is a positive outcome of this pre-NDA meeting. Ventrus Biosciences Inc (NASDAQ:VTUS) last trading day company shares ended up $1.24. Ventrus Biosciences Inc (NASDAQ:VTUS) distance from 50-day simple moving average (SMA50) is -42.69%. Analysts mean target price for the company is $2.50.